Vir Biotechnology Reports $96.3 Million Q3 Loss

The biotech posted a narrower third-quarter loss than a year earlier as research spending fell and cash reserves remained above $900 million.

Updated on Nov. 5, 2026 in Biotech

Vir Biotechnology Reports $96.3 Million Q3 Loss

Vir Biotechnology reported a third-quarter net loss of $96.3 million, or $0.57 per share, compared with $163.1 million in the same quarter of 2025. Lower research and development expenses drove the improvement.

Why it matters

The narrower loss and sizable cash position give Vir runway to advance its clinical programs. Investors are watching whether reduced spending can be sustained as the company moves toward later-stage data.

The third-quarter net loss fell from $163.1 million a year earlier, with research and development expenses dropping from $151.5 million to $80 million. The year-earlier quarter included a $75 million milestone expense, while higher manufacturing costs partly offset the decline and the company's ECLIPSE 1 outcome is still unknown.

The players

Vir Biotechnology

Vir Biotechnology is a clinical-stage biopharmaceutical company developing treatments for chronic viral infections, including chronic hepatitis delta, and it reported the quarterly results.

The details

Vir attributed the lower research and development spending to collaboration cost recoveries and the absence of a prior-year $75 million milestone payment. Higher manufacturing costs partly offset those savings during the quarter ended Sept. 30.

Sept. 30, 2025: Year-earlier quarter reported a $163.1 million net loss.
Sept. 30, 2026: Quarter ended with a reported $96.3 million net loss.
Fourth quarter of 2026: Vir expects topline data from the ECLIPSE 1 Phase 3 trial.
Second half of 2028: Current cash and investments are expected to fund operations.

The Big Picture

Vir's spending cuts come as it funds its ECLIPSE 1 Phase 3 trial of elebsiran and tobevibart for chronic hepatitis delta, with topline data due in late 2026. The company's cash runway into the second half of 2028 depends on that program progressing without a return to the heavier spending of 2025.

For patients with chronic hepatitis delta, the ECLIPSE 1 trial represents a possible future treatment option, though results are not yet available. The company's financial position suggests its pipeline work will continue through at least 2028.

The takeaway

Narrowing losses paired with a large cash reserve give Vir room to focus on its late-stage hepatitis delta program. Readers tracking biotech stocks should watch the ECLIPSE 1 readout due in late 2026 as the next major signal.

What happens next

Vir expects topline data from its ECLIPSE 1 Phase 3 trial in the fourth quarter of 2026, which could shape the company's next financial and clinical decisions.